Flying Brands Ltd (LON:FBDU) subsidiary, Imaging Biometrics (IB), said it has agreed a partnership which it reckons will "accelerate neuroscience research and increase accuracy in diagnostics support".
It hopes to do this by loading its software to a cloud-based platform called QMENTA, which provides data analysis and management for neuro experts.
IB's technology will be the first US Food & Drug Administration-cleared option on the system, which streamlines medical imaging workflow for running clinical trials.
Four modules offered
Being offered are modules IB Neuro, IB Delta T1 Maps, IB Diffusion and IB DCE.
"Our partnership with QMENTA enables efficient and immediate access to our quantitative imaging solutions to those involved in clinical trials and research," said IB chief executive Michael Schmainda.
"It is exciting to be part of QMENTA's neuro-centric platform and helping advance the understanding of neurological disorders."